Interview with Stephen Turley, Managing Director, Lundbeck Limited (UK)
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
Address: No. 2, 32 Caxton Road,
Shepherd’s Bush, London W12 8AJ,United Kingdom
Tel: +44 (0)20 ‐ 7229 4552
Web: http://www.dwlanguages.com/page.asp?node=2
DWL is a specialist translation service provider for the pharmaceutical industry providing Medical Translation into all European Union (EU) and European Economic Area (EEA) languages and many others – mainly “from” and “into” English
Established in 1962, our business has grown through dedication and commitment to quality and service. This is acknowledged by our many long-standing clients and is perhaps most clearly demonstrated by their recommendation of DWL to others.
By recognising the specific needs of this market, DWL delivers a quality Medical Translation Service due to its expertise in selecting the most suitable linguists in combination with reliable project management and quality control. We understand the need to be flexible and responsive in our service, and that accuracy and thoroughness remain essential – even within the tightest of project timelines.
DW Languages provides translation solutions for the following areas:
Medical translation services
Pharmaceutical translation
Regulatory affairs
Clinical trials
Medical research and manufacturing
Legal documentation
Medical publishing and marketing communications
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last…
See our Cookie Privacy Policy Here
